Condition: Hypereosinophilic Syndrome · Sponsor: GlaxoSmithKline
This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy. The study will recruit patients with a confirmed diagnosis of HES and who are on stable HES therapy for at least 4 weeks prior to randomization (Visit 2). Eligible participants must have uncontrolled HES with a history of repeated flare (≥2 flares in the previous 12 months) and blood eosinophil count of ≥1,000 cells/ microliter (μL) during Screening. Historical HES flares are defined as documented HES-related worsening of clinical symptoms or blood eosinophil counts requiring an escalation in therapy. Participants who meet the inclusion and exclusion criteria will be randomized in a 2:1 ratio to receive either depemokimab or placebo while continuing their SoC HES therapy.
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | San Diego, California, United States | Recruiting |
| GSK Investigational Site | Atlanta, Georgia, United States | Completed |
| GSK Investigational Site | Boston, Massachusetts, United States | Recruiting |
| GSK Investigational Site | Southfield, Michigan, United States | Withdrawn |
| GSK Investigational Site | Rochester, Minnesota, United States | Withdrawn |
| GSK Investigational Site | Manhasset, New York, United States | Completed |
| GSK Investigational Site | Cincinnati, Ohio, United States | Recruiting |
| GSK Investigational Site | Columbus, Ohio, United States | Recruiting |
| GSK Investigational Site | Charleston, South Carolina, United States | Recruiting |
| GSK Investigational Site | Nashville, Tennessee, United States | Completed |
| GSK Investigational Site | Salt Lake City, Utah, United States | Recruiting |
| GSK Investigational Site | Buenos Aires, Argentina | Recruiting |
+ 80 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05334368